Objective: To analyze the prognostic factors of AML children with CBFβ/MYH11 positive.
Methods: Twenty-eight children with CBFβ/MYH11 positive treated in our hospital from May 2012 to June 2018 were selected, the clinical data and curative were analyzed and evaluated.
Results: Five-year OS and 5-year EFS rate of CBFβ/MYH11 positive AML children was 76.8% and 64.0% efficacy, respectively. Univariate analysis results showed that the OS rate of CBFβ/MYH11 positive AML children with WBC<60.0×109/L was 86.5%, which was significantly higher than those of CBFβ/MYH11 positive AML children with WBC≥60.0×109/L (χ2=3.891, P<0.05). The EFS rate of CBFβ/MYH11 positive AML children with WBC<60.0×109/L was 76.0%, which was significantly higher than those of AML children with WBC≥60.0×109/L (χ2=4.588, P<0.05). The EFS rate of CBFβ/MYH11 positive AML children with XRCC-Thr241Met wild type was 77.9%, which was significantly higher than those of AML children with XRCC-Thr241Met variant (χ2=3.960, P<0.05). Cox multivariate survival analysis results showed that WBC level at initial diagnosis was the risk factor for OS rate. The WBC level and XRCC-Thr241Met type at initial diagnosis were the risk factors for EFS rate.
Conclusion: WBC level and XRCC-Thr241Met genotype at initial diagnosis are the major affecting factors for prognosis of AML children with CBFβ/MYH11 positive.
题目: 伴CBFβ/MYH11阳性初诊AML患儿的预后影响因素分析.
目的: 分析伴CBFβ/MYH11阳性初诊急性髓系白血病（AML）患儿的预后影响因素.
方法: 选取2012年5月至2018年6月本院收治的原发性初治伴inv（16）/ CBFβ-MYH11阳性AML患儿28例，对其临床资料及治疗效果等进行分析和评估.
结果: 所有患儿5年总生存（OS）率76.8%，5年无事件生存（EFS）率64.0%。单因素分析结果显示，WBC<60.0×109/L的患儿OS率为86.5%，显著性高于WBC≥60.0×109/L的患儿的50.0%（χ2=3.891，P<0.05）。WBC <60.0×109/L的患儿EFS率为76.0%，显著性高于WBC≥60.0×109/L的患儿的37.5%（χ2=4.588，P<0.05）。XRCC-Thr241Met野生型患儿EFS率为77.9%，显著性高于XRCC-Thr241Met变异型患儿的43.6%（χ2= 3.960，P<0.05）。Cox多因素生存分析显示，初诊WBC水平为影响该类患儿OS率的危险因素，初诊WBC水平及XRCC-Thr241Met是否野生型为影响该类患儿EFS率的危险因素.
结论: 初诊WBC水平及XRCC-Thr241Met基因型为影响伴CBFβ/MYH11阳性初诊AML患儿预后的主要因素.